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In our earlier studies we have demonstrated the 
presence of elevated sensitivity of drug resistant tumors 
to adoptive immunotherapy with the use of autologous 
IL-2 activated lymphocytes (LAK). In particular, such 
sensitivity was demonstrated in vivo and in vitro for 
В16 melanoma, transplanted МC-rhabdomyosarcoma, 
soft tissue sarcoma of locomotor system, endometrial 
and ovarian cancers [1–3], as well as for malignant hu-
man breast tumors [4]. However, the reason for elevated 
sensitivity of drug resistant tumors to immunotherapy, 
in particular, LAK-therapy, remains unknown, and the 
respective data are scarce [5].
To address this problem, we decided to analyze 
expression of E-cadherin by malignant human breast 
cancer cells. E-cadherin is a member of a family of 
calcium-dependent adhesion molecules mediating 
cell adhesion in different tissues, and a key regulator 
of adhesive properties of epithelial cells [6, 7]. Similarly 
to other members of the family, E-cadherin contains 
5 extracellular domains one of which contains intercel-
lular domain and can create complexes with α and β 
catenins and р120 protein [7, 8]. Due to formation of 
such complexes, E-cadherin possesses a number of 
regulatory functions, in particular, participates in mor-
pho- and embryogenesis [9, 10]. Its multifunctionality 
leads to a special interest for researchers studying 
E-cadherin expression in different pathologies.
Altered expression of E-cadherin is shown to be 
related to formation of drug resistance of breast cancer 
cell lines and primary cell cultures, because E-cadhe-
rin, like other adhesion molecules, provides homotypic 
adhesion, the decrease of which promotes develop-
ment of drug resistance [4, 11–13]. Also E-cadherin 
related decrease of adhesive properties is directly 
linked to survival of circulating tumor cells resistant to 
some cytostatic drugs. In particular, it has been shown 
that development of drug resistance of circulating 
prostate cancer cells is associated with the decrease 
of E-cadherin, β4-integrin, and γ-catenin expression, 
and with elevation of Bcl-2 expression [14].
It’s necessary to note that decreased expression 
of E-cadherin in breast cancer cells and development 
of drug resistance are associated with a number of 
alterations on molecular, genetic and epigenetic levels 
(in particular, altered DNA methylation and р53 tran-
scription, altered expression of some antiapoptotic 
molecules, etc.) [12, 15, 16].
Possible mechanisms of influence of decreased 
E-cadherin expression on formation of drug resistance 
are poorly studied yet. It is could be explained partially 
by the involvement of E-cadherin in a number of various 
biological processes. In particular, it has been shown 
that E-cadherin interacts with EGF receptor and inhibits 
EGF-induced signals [17], but not the activity of other 
receptors [18]. The switch of E-cadherin to its isoforms, in 
particular, to N-cadherin, that is characteristic for breast 
cancer, may play a role in drug resistance formation [8, 
19]. According to the recent data, decreased E-cadherin 
expression in epithelial tumors depends on mutation 
of genes coding E-cadherin, α- and β-catenins, р120, 
altered DNA methylation and transcription control [8].
Above mentioned findings made it important to 
examine the correlation of E-cadherin expression with 
the increased sensitivity of drug resistant breast tumor 
cells to action of LAK.
MATERIALS AND METHODS
The study has been performed on clinical materials 
obtained from the patients with benign (n = 12) and 
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malignant (n = 20; diagnosis — infiltrative carcinoma) 
breast tumors cured in the Department of Surgery 
of Kyiv Hospital № 1 (Kyiv, Ukraine). Tumor tissue 
samples (tumor explants and tumor tissue sections) 
were obtained from surgically resected specimens. 
Peripheral blood lymphocytes (PBL) from these pa-
tients have been analyzed. The study was performed 
in accordance with international and state rules for 
bioethics.
To obtain lymphokine-activated lymphocytes (LAK) 
from PBL (3 x 106 cells/ml), cells were incubated 
with recombinant interleukin-2 (RIL-2; 1000 MU/ml) 
(BIOTECH, Russia) for 2 h at 37 °С in the athmosphere 
of 5% СО2, and washed twice.
Antitumor action of activated and nonactivated 
lymphocytes toward tumor explants was studied by 
their co-cultivation for 5 days in double diffusion cham-
bers. After cultivation the preparations were fixed in 
spirit-formol (Makrochim, Ukraine) for 1 h, stained with 
Carazzi’s hematoxylin (Fluka, Switzerland) for 20 min, 
passed through the spirits of increased concentration 
and treated with xylene; then preparations are covered 
by Canadian balsam and examined by microscopy 
(JENAVAL microscope, Germany). Evaluation of anti-
tumor activity of lymphocytes was done on the basis of 
morphological patterns of explant’s growth (ability of 
cell to migrate from explant, formation of monolayer of 
different density, and of cell conglomerates, etc.).
Individual sensitivity of tumor explants to chemo-
therapeutic drugs (doxorubicine (0.02 mg/ml, Ebewe, 
Austria), cyclophosphane (0.006 mg/ml, Olanpharm, 
Latvia), 5-fluorouracil (0.006 mg/ml Ebeve, Austria), 
metothrexate (0.005 mg/ml, Teva Pharmaceutical 
Industries LTD, Israel) was determined by cultivation 
of explants in diffusion chambers in culture medium 
supplemented with mentioned drugs as described 
in [20].
To determine the expression of E-cadherin, p53 
(DacoCytomation, Denmark), and nuclear antigen of 
proliferating cells (mAb IPO-38, IEPOR NASU, Kiev, 
Ukraine) in tumor cells, paraffin sections of tumors 
were analyzed by immunohistochemistry with the use 
of respective monoclonal antibodies, and seconda-
ry complex EnVision (DacoCytomation, Denmark). 
Expression of lectin from soybean, coral bean, lentil 
and PHA receptors (SMI Lectinotest, Ukraine) on 
lymphocytes was studied by immunocytochemistry. 
The level of expression of mentioned markers was 
evaluated by semiquantitative method where integral 
index of expression level was determined by the sum 
of scores < for the percent of stained cells (score 1 — 
≤ 10%, score 2 — 10–30%, score 3 — 30–45%, score 
4 — 45–60%, score 5 — ≥60%) and staining intensity 
(score 1 — low, score 2 — medium, score 3 — high) 
[21]. Expression of CD54, CD11b, and nuclear antigen 
of proliferating cells on lymphocytes was studied by the 
method of indirect immunofluorescence with the use 
of respective monoclonal antibodies (IEPOR NASU) at 
the dilution of 40 μg/ml.
RESULTS AND DISCUSSION
By determination of individual sensitivity of malig-
nant tumors to mentioned chemopreparations it has 
been shown that the tumors of 15 patients are resistant 
to one, two, three or four cytostatics, in most cases — 
to doxorubicine and methotrexate. Only in 5 cases, 
the tumors were sensitive to all four drugs. So, the 
patients with malignant tumors were distributed into 
two groups — with drug resistant malignant human 
breast tumors (DRHBT) and drug sensitive breast tu-
mors (DSHBT), and the third group (the patients with 
benign breast tumors (BBT)) served as a control.
In all groups, the expression of E-cadherin, nuclear 
antigen of proliferating cells and p53 by tumor cells has 
been studied. Evaluation of E-cadherin expression has 
demonstrated that in DRHBT cells it was significantly lo-
wer than in DSHBT or BBT cells (3.3 ± 0.7 vs 4.8 ± 0.5 and 
5.9 ± 0.9, respectively) (Table 1). Fig. 1 presents the level 
of E-cadherin expression in each tumor case. In DRHBT 
group an integral index of E-cadherin expression level 
reached only score 3 in 60% of cases, while in DSHBT 
or BBT groups it was significantly higher.
Table 1. Expression of E-cadherin, p53 and nuclear antigen of proliferating cells 
in human benign and malignant breast tumor cells (semiquantative analysis)
Groups of patients
Integral score of expression level (M ± m)
Е-cadherin р53
Nuclear antigen 
of proliferating 
cells
Patients with benign neoplasms 
(n = 12)
5.9 ± 0.9 5.2 ± 1.8 4.2 ± 0.8
Patients with drug resistant 
malignant breast tumors (n = 15)
3.3 ± 0.7*, ** 3.4 ± 0.7 6.5 ± 0.8**
Patients with drug sensitive 
malignant breast tumors) (n = 5)
4.8 ± 0.5 4.2 ± 0.8 5.4 ± 0.5
*The difference between the groups of drug sensitive and resistant tumors 
is statistically significant (р < 0.05); **the difference between the groups 
of benign and malignant drug resistant tumors is statistically significant 
(р < 0.05).
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Fig. 1. E-cadherin expression in human breast tumor cells 
(semiquantitative analysis)
The levels of nuclear antigen of proliferating cells 
expression were significantly different between BBT 
cells and DRHBT cells (6.5 ± 0.8 and 4.2 ± 0.8, re-
spectively), while in DSHBT group this index showed 
only a tendency to be higher (see Table 1, Fig. 2). 
Thus, DRHBT cells were characterized by low level 
of E-cadherin expression and high level of nuclear 
antigen of proliferating cells expression.
There were no significant differences in expression 
levels of p53 between the groups. However, individual 
variations in each group were rather different.
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Fig. 2. Expression level of nuclear antigen of proliferating cells 
in human breast tumor cells (semiquantitative analysis)
We have studied antitumor activity of LAK towards 
tumor explants from the patients of all groups taking 
into account data on expression of E-cadherin and 
nuclear antigen of proliferating cells. The most pro-
nounced activity of LAK was directed against DRHBT. 
DRHBT explants growth was significantly suppressed, 
while in control BBT and DSHBT groups, formation 
of monolayer of various densities was observed. In 
DRHBT group only single cells or no cells migrated, 
or in some cases tumor destruction was observed 
(Fig. 3, a, b).
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Fig. 3. Morphological analysis of the growth of explants from 
drug resistant (a) and sensitive (b) malignant tumors and benign 
breast tumors upon the action of LAK: 1 — no migration; tumor 
destruction; 2 — no migration; 3 — migration of single cells; 
4 — initial stage of monolayer formation; 5 — monolayer of low 
density; 6 — monolayer of medium density
To analyze whether some proteins expressed on 
LAK surface were involved in LAK interaction with tu-
mor cells, expression levels of some lectin receptors 
(soybean, coral bean, lentil, PHA) and CD54 and CD11b 
were examined (Table 2). There were no significant dif-
ferences in CD54, СD11b, receptors for lectins (coral 
bean, lentil, PHA) expression levels between the studied 
groups. However, lymphocytes from DRHBT group were 
characterized by significantly higher expression level of 
soybean lectin receptor than in DSHBT and BBT groups 
(47.5 ± 5.4 vs 35.3 ± 4.5; 27.5 ± 3.4, respectively). 
It could be supposed that soybean receptor may be 
involved in antitumor activity of LAK.
So, DRHBT cells were characterized by the reverse 
relation between expression levels of E-cadherin and 
nuclear antigen of proliferating cells. Marked antitumor 
action of LAK against these tumors was associated with 
elevated expression of soybean lectin receptor.
The aim of the present work was to examine if there 
any correlation between E-cadherin and the expres-
sion of some other markers with elevated sensitivity of 
resistant tumor cells to the action of LAK. Expression 
of a number of markers in lymphocytes themselves 
has been studied as well. It was shown that decreased 
E-cadherin expression was the most marked alteration 
of DRHBT cells compared with DSHBT and BBT cells.
It is known that decrease of E-cadherin expression 
is accompanied by dissociation of E-cadherin/catenin 
complex leading to altered activity of some signaling 
pathways (Wnt, PKD-1, Int-2 etc.), nuclear accumula-
tion of β-catenin, and activation of transcription factors 
(NF-B, Ap-1 and other) [22–25]. Finally, all mentioned 
intracellular processes that reflect molecular changes in 
cells upon the decrease of E-cadherin expression, are 
accompanied by elevated proliferation of tumor cells 
[26], which is in accordance with our data.
Unfortunately, there are just few studies on a relation 
between tumor cells proliferation and antitumor action 
of LAK, but we consider the marked proliferation of drug 
resistant tumor cells as a factor favoring LAK activity.
There are interesting data showing that disturbed 
intercellular adhesion promote antibody-dependent 
cell cytotoxicity. These data were obtained with the use 
of anti-adhesive antibodies and intestinal carcinoma 
on a model of spheroid formation. The use of these an-
tibodies positively regulated antibody-dependent cell 
cytotoxicity mediated by FcγRIII receptor [27]. There, 
its looks reasonable to use anti-adhesive drugs (in 
particular SHЕ78-7 monoclonal antibodies) in therapy 
of some tumors [28].
Elevated expression of soybean lectin receptor in 
lymphocytes from patients with drug resistant tumors 
may be related to promotion of antitumor activity of LAK. 
Table 2. Expression of CD54, CD11b, and lectins receptors by LAK from the patients with benign and malignant breast tumors
Groups of patients
Percent of cells expressing the marker protein (M ± m)
CD54 CD11b Lectins receptorsSoybean Coral bean Lentil PHA
Patients with benign neoplasms (n = 12) 12.2 ± 3.4 55.2 ± 6.3 28.2 ± 3.1 27.5 ± 3.4 3.5 ± 1.2 76.2 ± 2.2
Patients with drug resistant malignant breast tumors (n = 15) 16.4 ± 4.4 58.3 ± 5.3 47.5 ± 5.4* 31.8 ± 2.7 3.2 ± 1.4 70.0 ± 3.4
Patients with drug sensitive malignant breast tumors (n = 5) 15.1 ± 4.0 40.2 ± 7.4 35.3 ± 4.5 26.3 ± 5.1 3.0 ± 1.6 66.7 ± 2.5
*The difference between the groups of benign and malignant tumors is statistically significant (р < 0.05).
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In is known that N-acetyl-D-galactosamine — carbo-
hydrate present on a surface of a number of epithelial 
tumors — serves as a ligand for soybean lectin recep-
tor. That is why the data on a role of N-glycosylation 
for E-cadherin-mediated cell adhesion are of special 
interest [13]. One may suppose that interaction between 
soybean receptor on lymphocytes with its ligand on 
tumor cells may promote their antitumor action.
ACKNOWLEDGEMENT
We thank L.Yu. Kovaleva for collaboration, and 
N.Yu. Lukyanova for valuable advices.
REFERENCES
Berezhnaya NM, Kovalchuk EV, Vinnichuk YD, 1. et al. 
Experimental immunotherapy of mice with transplated 
MC-rhabdomiocarcoma resistant to doxorubicin. Exp Oncol 
2004; 26: 63–7.
Berezhnaya NM, Vinnichuk YD, Konovalenko VF, 2. et al. 
The sensitivity of chemoresistant human tumor explants to 
lysis by activated and nonactivated autologous lymphocytes: 
a pilot study. Exp Oncol 2005; 27: 303–7.
Belova OB, Vinnichuk UD, Shlakhovenko VA, 3. et al. Effi-
cacy of different immunotherapy approaches toward treatment 
of doxorubicin-resistant and doxorubicin-sensitive transplan-
table rhabdomyosarcoma. Exp Oncol 2007; 29: 272–6.
Vinnichuk YD, Belova ОB, Кirnasovskaya ЕА, 4. et al. The 
features of growth of the benign and malignant breast tumor 
in diffusion chambers. Oncology 2009; 11: 174–9.
Berezhnaya NM, Chekhun VF. 5. System of interleukins 
and cancer. Kyiv: DIA, 2000; 224 p (In Russian).
Woodberr T, Suscovich TJ, Henry6.  L M, et al. αE7 (CD103) 
expression identifies a highly active, tonsil-resident effector-
memory CTL population. J Immunol 2005; 17: 4355–62.
Taneyhill LA, Coles EG, Bronner-Fraser M. 7. Snail2 directly 
represses cadherin6B during epithelial-to-mesenchymal transi-
tions of the neural crest. Development 2007; 134: 1481–90.
Wheelock M, Shintani Y, Maeda M, 8. et al. Cadherin 
switching. J Cell Sci 2008; 121: 727–35.
Feltes CM, Kudo A, Blaschuk O, 9. et al. An alternatively 
spliced cadherin-11 enhances human breast cancer cell inva-
sion. Cancer Res 2002; 62: 6688–97.
Moore R, Champeval D, Denat L, 10. et al. Involvement of 
cadherins 7 and 20 in mouse embryogenesis and melanocyte 
transformation. Oncogene 2004; 23: 6726–35.
Shpyleva SI, Yurchenko OV, Volkova KD, 11. et al. Value 
of tumor biomarkers with the different drug resistance pheno-
type for current of disease at breast cancer patients. Oncology 
2007; 9: 110–4.
Chekhun VF, Lukyanova NY, Kovalchuk O, 12. et al. Epi-
genetic profiling of multidrug-resistant human MCF-7 breast 
adenocarcinoma cells reveals novel hyper- and hypomethylated 
targets. Mol Cancer Ther 2007; 6: 1089–98.
Zhao H, Liang Y, Xu Z, 13. et al. N-glycosylation affects the 
adhesive function of E-Cadherin through modifying the com-
position of adherens junctions (AJs) in human breast carcinoma 
cell line MDA-MB-435. J Cell Biochem 2008; 104: 162–75.
Howard EW, Leung SC, Yuen HF, 14. et al. Decreased ad-
hesiveness, resistance to anoikis and suppression of GRP94 are 
integral to the survival of circulating tumor cells in prostate 
cancer. Clin Exp Metastasis 2008; 25: 497–508.
Wang L, Li Z, Wang C, 15. et al. E-cadherin decreased human 
breast cancer cells sensitivity to staurosporine by up-regulating 
Bcl-2 expression. Arch Biochem Biophys 2009; 481: 116–22.
Criswell TL, Arteaga CL. 16. Modulation of NFκB Activity 
and E-cadherin by the Type III transforming growth factor  
receptor regulates cell growth and motility. J Biol Chem 2007; 
282: 32491–500.
Qian X, Karpova T, Sheppard AM, 17. et al. E-cadherin-me-
diated adhesion inhibits ligand-dependent activation of diverse 
receptor tyrosine kinases. EMBO J 2004; 23 (8): 1739–48.
Perrais M, Chen X, Perez-Moreno M, 18. et al. E-cadherin 
homophilic ligation inhibits cell growth and epidermal growth 
factor receptor signaling independently of other cell interac-
tions. Mol Biol Cell 2007; 18: 2013–25.
Hazan RB, Phillips GR, Qiao RF, 19. et al. Exogenous ex-
pression of N-cadherin in breast cancer cells induces cell migra-
tion, invasion, and metastasis. J Cell Biol 2000; 148: 779–90.
Cheshuk VЕ, Berezhna NМ, Kovalchuk ОV, Koz-20. 
lenko ОV. The means for determination of indications for 
chemotherapy of breast cancer. Patent of Ukraine № 50595А 
from 15.10.2002 (In Ukrainian).
Samsonova ЕА, Maximova NA, Urmancheeva AF, 21. et al. 
Expression of receptors of estrogens, progesterone and Неr2 on-
coprotein as an index of clinical course and outcome of endo-
metryoid adenocarcinoma of corpus uteri (immunohistochemical 
study). Voprosi Oncologii 2004; 50: 196–201 (In Russain).
Brembeck FH, Rosário M, Birchmeier W. 22. Balancing 
cell adhesion and Wnt signaling, the key role of beta-catenin. 
Curr Opin Genet Dev 2006; 16: 51–9.
Hollmann CA, Kittrell FS, Medina D, Butel JS. 23. 
Wnt-1 and int-2 mammary oncogene effects on the beta-
catenin pathway in immortalized mouse mammary epithelial 
cells are not sufficient for tumorigenesis. Oncogene 2001; 
20: 7645–57.
Du C, Jaggi M, Zhang C,24.  et al. Protein kinase 
D1-mediated phosphorylation and subcellular localization of 
beta-catenin. Cancer Res 2009; 69: 1117–24.
Chua HL, Bhat-Nakshatri P, Clare SE, 25. et al. 
NF-kappaB represses E-cadherin expression and enhances 
epithelial to mesenchymal transition of mammary epithelial 
cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 
2007; 26: 711–24.
Szakács G, Gottesman MM. 26. Comparing solid tumors 
with cell lines: implications for identifying drug resistance 
genes in cancer. Mol Interv 2004; 4: 323–5.
Green SK, Karlsson MC, Ravetch JV, 27. et al. Disruption 
of cell-cell adhesion enhances antibody-dependent cellular 
cytotoxicity: implications for antibody-based therapeutics of 
cancer. Cancer Res 2002; 62: 6891–900.
Green SK, Francia G, Isidoro C, 28. et al. Antiadhesive 
antibodies targeting E-cadherin sensitize multicellular tumor 
spheroids to chemotherapy in vitro. Mol Cancer Ther 2004; 
3: 149–59.
Copyright © Experimental Oncology, 2009
